Posted by Michael Wonder on 11 Jul 2022
Arcutis Biotherapeutics announces Health Canada accepts for review the new drug submission for roflumilast cream for adults and adolescents with plaque psoriasis
11 July 2022 - Submission supported by positive clinical data from the pivotal Phase 3 DERMIS-1 and DERMIS-2 clinical studies, as well as results from long-term safety studies.
Arcutis Biotherapeutics today announced that Health Canada has accepted for review the new drug submission for roflumilast 0.3% topical cream for the treatment of plaque psoriasis in adults and adolescents.
The target action date is 30 April 2023.
